LDS/Medical Tests/Rhesus D (Rh D), Typing

Rhesus D (Rh D), Typing

The Rh antigens are encoded by the RHD and RHCE genes. In RhD-negative individuals the RHD gene is absent or grossly deleted. Individuals that express RHD gene (antigen) are RhD-positive. The Rh proteins carry Rh antigens but are only expressed on the erythrocyte surface. There are three classified RhD variants: partial D variants, weak D types, or nonfunctional and D-elution alleles. Partial D variants lack D antigen epitopes, and weak D types generally present all D epitopes, albeit some epitopes show variability depending on the monoclonal anti-D used for testing. Individuals who harbor partial D variant alleles have the potential to make alloanti-D, whereas common weak D types do not pose such a risk. The distinction is important because the appropriate assignment of D antigen status determines the selection of blood products and perinatal management to prevent anti-D hemolytic disease of the fetus and newborn.

Anti-Rh antibodies are the leading cause of hemolytic disease of the newborn and delayed hemolytic transfusion reactions. This test is used for screening pregnant women for administration of Rh immune globulin, for pre-transfusion testing, and for confirmation of Rh(D)-negative donor units. Of Rh(D)-negative persons receiving a single Rh(D)- positive blood unit, 50–75% will develop anti-D (age and immune status dependent). The blood of all donors and recipients is therefore routinely tested for D antigen, so that D-negative recipients can be given D-negative blood when appropriate. Donor blood must also be tested for a weak form of D antigen, previously called Du, and must be labeled D-positive if "weak D" is detected. It is not required to test the recipient blood specimen for weak D.

  • To determine the need for administration of Rh(D) immunoglobulin
  • Pre-transfusion testing
  • Donor unit testing

Positive in:

  • Patients expressing Rh(D) antigen
  • Patients expressing weak D and partial D antigen

Negative in:

  • Patients not expressing Rh(D) antigen

Patients are usually reported as positive or negative based on the presence or absence of the D antigen.

 

Serologic Testing. The method involves an in vitro system of exposing the patient’s red blood cells to a known antiserum and grading the reactivity (usually agglutination).

Serum (Red top) tube, Plasma (lavender top) tube.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
ABO, Indirect Antiglobulin Test, Direct Antiglobulin Test, Antibody screen and identification, Rh Genotyping by Molecular Method.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Technical Manual of the American Association of Blood Banks, 15th ed. American Association of Blood Banks (2005).
  • Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).
  • Transfusion. 2004;44:703. [PMID: 15104651]
  • Clin Lab. 2002;48(1-2):53-9. [PMID: 11833677]
  • Blood. 2000 Jan 15;95(2):375-87. [PMID: 10627438]
  • Blood Rev. 1994 Dec;8(4):199-212. [PMID: 7888828]